Final Phase III data support AcelRx pain drug/device
This article was originally published in Scrip
Executive Summary
The AcelRx Pharmaceuticals sufentanil NanoTab PCA (patient-controlled analgesia) System provided significant pain relief during the three days following orthopedic surgery for patients who underwent knee or hip replacements in the third of three Phase III clinical trials to support a new drug application (NDA) to the US FDA later this year.